Egan Jennifer A, Ionescu Marina C, Eapen Elizabeth, Jones Joan G, Marshall David S
Department of Pathology, Albert Einstein College of Medicine and Jack D Weiler Hospital of Montefiore Medical Center, Bronx, New York 10461, USA.
Int J Gynecol Pathol. 2004 Apr;23(2):119-22. doi: 10.1097/00004347-200404000-00005.
Wilms' tumor antibody (WT1) has recently been reported to be reactive in most ovarian and peritoneal serous carcinomas, but few studies have looked at WT1 reactivity in endometrial carcinomas. p53, like WT1, is a tumor suppressor gene and in its mutated form is frequently present in endometrial serous carcinoma. Routine immunohistochemical staining for p53 and WT1 was performed in 70 endometrial carcinomas (39 endometrioid and 31 serous) of varying differentiation using tissue microarrays. Only 2 (7.5%) serous carcinomas and none of the endometrioid carcinomas (0%) were reactive for WT1. p53 immunoreactivity was found in 26 (83.9%) serous carcinomas and in 2 (5.1%) endometrioid carcinomas. We conclude that WT1 and p53 expression are not related and that WT1 expression in endometrial serous carcinoma differs from that of its extrauterine counterparts.
肾母细胞瘤抗体(WT1)最近有报道称在大多数卵巢和腹膜浆液性癌中呈阳性反应,但很少有研究关注WT1在子宫内膜癌中的反应性。p53与WT1一样,是一种肿瘤抑制基因,其突变形式在子宫内膜浆液性癌中经常出现。使用组织芯片对70例不同分化程度的子宫内膜癌(39例子宫内膜样癌和31例浆液性癌)进行了p53和WT1的常规免疫组化染色。只有2例(7.5%)浆液性癌对WT1呈阳性反应,而子宫内膜样癌无一例(0%)呈阳性反应。在26例(83.9%)浆液性癌和2例(5.1%)子宫内膜样癌中发现了p53免疫反应性。我们得出结论,WT1和p53的表达无关,且子宫内膜浆液性癌中WT1的表达与其子宫外对应物不同。